Page last updated: 2024-12-05

phenylglyoxal

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Phenylglyoxal is a dicarbonyl compound with the formula C6H5COCHO. It is a yellow oil that is soluble in water and organic solvents. Phenylglyoxal is a versatile building block for organic synthesis and has been used in the preparation of a wide range of compounds, including pharmaceuticals, dyes, and polymers. Phenylglyoxal is a potent inhibitor of the enzyme glyoxalase I, which is involved in the detoxification of methylglyoxal, a reactive carbonyl species that can damage cells. Phenylglyoxal has also been shown to have anti-cancer activity and is currently under investigation as a potential therapeutic agent. Phenylglyoxal is a valuable tool for studying the role of dicarbonyl compounds in biological processes. It is also a useful reagent for organic synthesis, and its applications in this area continue to expand. Phenylglyoxal is a promising lead compound for the development of new drugs and other therapeutic agents.'

Cross-References

ID SourceID
PubMed CID14090
CHEMBL ID233632
CHEBI ID88868
SCHEMBL ID57493
MeSH IDM0016564

Synonyms (62)

Synonym
4-07-00-02129 (beilstein handbook reference)
unii-n45g3015pa
n45g3015pa ,
AKOS009031532
nsc627436
nsc-627436
phenylglyoxal treated casein
phenylglyoxal treated bsa
oxo-phenyl-acetaldehyde
2-oxo-2-phenyl-acetaldehyde
nsc26909
nsc-26909
oxo(phenyl)acetaldehyde
NCGC00091619-01
nsc 26909
benzeneacetaldehyde, alpha-oxo-
ai3-22132
einecs 214-036-1
ccris 966
nsc 156299
brn 1854721
benzoylcarboxaldehyde
benzeneacetaldehyde, alpha-oxo-, monohydrate
phenylethanedione
phenylglyoxal ,
alpha-oxobenzeneacetaldehyde
glyoxal, phenyl-
benzoylformaldehyde
1074-12-0
benzeneacetaldehyde, .alpha.-oxo-
nsc-156299
nsc156299
phenyl glyoxal
chebi:88868 ,
CHEMBL233632
2-oxo-2-phenylacetaldehyde
P0652
A18068
NCGC00091619-02
NCGC00257831-01
tox21_200277
dtxsid8025888 ,
cas-1074-12-0
dtxcid705888
FT-0633297
AB00817
1-phenylethanedione
SCHEMBL57493
oxo(phenyl)acetaldehyde #
phenylglyoxal, aldrichcpr
benzeneacetaldehyde, a-oxo-
Q5934181
mfcd00006959
197302-59-3
AS-50086
2-hydroxy-2-phenylethenone
benzoyl formaldehyde
SY047494
O10845
a-hydroxy phenylketene
EN300-33982
Z1954804411

Research Excerpts

Overview

Phenylglyoxal is a dicarbonyl compound known to react with guanidine groups. It has been shown to destroy the activity of interleukin 1 (former called LAF, lymphocyte-activating factor)

ExcerptReferenceRelevance
"Phenylglyoxal is a dicarbonyl compound known to react with guanidine groups such as that of the DNA base guanine, therefore suggesting that phenylglyoxal could induce DNA damage and have anticancer activity."( Guanidine-reactive agent phenylglyoxal induces DNA damage and cancer cell death.
Austin, CA; Burgos-Morón, E; Calderón-Montaño, JM; López-Lázaro, M; Mateos, S; Orta, ML; Pastor, N; Perez-Guerrero, C, 2012
)
1.4
"Phenylglyoxal is an arginine-specific reagent which has been shown to destroy the activity of interleukin 1 (former called LAF, lymphocyte-activating factor)."( Enhanced breakdown in vitro of bovine articular cartilage proteoglycans by conditioned synovial medium. The effect of phenylglyoxal.
Klämfeldt, A, 1985
)
1.2
"Phenylglyoxal is found to be a potent inhibitor of sulfate equilibrium exchange across the red blood cell membrane at both pH 7.4 and 8.0. "( Anion transport in red blood cells and arginine-specific reagents. Interaction between the substrate-binding site and the binding site of arginine-specific reagents.
Julien, T; Zaki, L, 1985
)
1.71

Treatment

ExcerptReferenceRelevance
"Treatment with phenylglyoxal inactivates the enzyme with concomitant modification of 2.7 mol of arginyl residues/mol of subunit."( Chemical modification of a functional arginyl residue (Arg 292) of mitochondrial aspartate aminotransferase. Identification as the binding site for the distal carboxylate group of the substrate.
Christen, P; Sandmeier, E, 1982
)
0.6

Toxicity

ExcerptReferenceRelevance
" The cytotoxic effects of the photosensitizers on both human submandibular gland (HSG) adenocarcinoma cell line and primary human gingival fibroblast (HGF) showed that the 50% toxic concentration (TC(50)) declined in the order: CQ>BP>9-F>BZ."( The production of reactive oxygen species by irradiated camphorquinone-related photosensitizers and their effect on cytotoxicity.
Atsumi, T; Fujisawa, S; Iwakura, I; Ueha, T, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenylacetaldehydes
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (18)

PathwayProteinsCompounds
superpathway of glycolysis, pyruvate dehydrogenase, TCA, and glyoxylate bypass3989
superpathway of b heme biosynthesis from glycine1046
heme b biosynthesis I (aerobic)1428
CDP-diacylglycerol biosynthesis I1317
TCA cycle I (prokaryotic)1741
pyruvate to cytochrome bo oxidase electron transfer535
3,8-divinyl-chlorophyllide a biosynthesis II (anaerobic)934
acetate and ATP formation from acetyl-CoA I1223
mixed acid fermentation3276
superpathway of penicillin, cephalosporin and cephamycin biosynthesis1169
deacetylcephalosporin C biosynthesis444
L-threonine degradation II331
L-threonine degradation III (to methylglyoxal)328
superpathway of bacteriochlorophyll a biosynthesis2270
aminopropanol phosphate biosynthesis II328
superpathway of L-threonine metabolism2172
superpathway of glyoxylate bypass and TCA1855
methanogenesis from acetate526

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency8.91250.004023.8416100.0000AID485290
acetylcholinesteraseHomo sapiens (human)Potency10.73810.002541.796015,848.9004AID1347395; AID1347397; AID1347398; AID1347399
RAR-related orphan receptor gammaMus musculus (house mouse)Potency68.65940.006038.004119,952.5996AID1159521; AID1159523
GLI family zinc finger 3Homo sapiens (human)Potency24.36130.000714.592883.7951AID1259392
AR proteinHomo sapiens (human)Potency54.53810.000221.22318,912.5098AID1259247
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency2.81840.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency68.65940.001022.650876.6163AID1224838; AID1224893
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency34.38410.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency49.02010.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency68.65940.001530.607315,848.9004AID1224841; AID1224842; AID1259401
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency21.89650.023723.228263.5986AID743222
thyroid stimulating hormone receptorHomo sapiens (human)Potency19.51300.001628.015177.1139AID1224843; AID1224895; AID1259385
activating transcription factor 6Homo sapiens (human)Potency61.71270.143427.612159.8106AID1159516; AID1159519
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency39.97480.057821.109761.2679AID1159526; AID1159528
heat shock protein beta-1Homo sapiens (human)Potency49.02010.042027.378961.6448AID743210
mitogen-activated protein kinase 1Homo sapiens (human)Potency31.62280.039816.784239.8107AID995
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency74.97800.000627.21521,122.0200AID651741
Nuclear receptor ROR-gammaHomo sapiens (human)Potency66.82420.026622.448266.8242AID651802
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency68.65940.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency68.65940.011912.222168.7989AID651632
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (31)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (17)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (13)

Processvia Protein(s)Taxonomy
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1408667Inhibition of rat liver ACLY2018European journal of medicinal chemistry, Sep-05, Volume: 157ATP citrate lyase (ACLY) inhibitors: An anti-cancer strategy at the crossroads of glucose and lipid metabolism.
AID296481Inhibition of acetosyringone-induced virB::lacZ expression in Agrobacterium tumefaciens A348/pSW2092007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Rational design of inhibitors of VirA-VirG two-component signal transduction.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (605)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990261 (43.14)18.7374
1990's187 (30.91)18.2507
2000's92 (15.21)29.6817
2010's58 (9.59)24.3611
2020's7 (1.16)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 38.11

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index38.11 (24.57)
Research Supply Index6.42 (2.92)
Research Growth Index4.27 (4.65)
Search Engine Demand Index57.29 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (38.11)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.16%)5.53%
Reviews4 (0.65%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other609 (99.19%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]